Physician profile
Daniel A Langer
NPI 1740268481
$6,723.50
in general payments reported to CMS, 2019-2025
38 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $458 · 2021: $349 · 2022: $1,226 · 2023: $911 · 2024: $1,030 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973 · Education: $47.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,973.36 |
| Education | $47.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,745.52 | 2019-2025 | |
| Gilead Sciences, INC. | $798.31 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $654.28 | 2019-2025 | Tremfya |
| Pfizer INC. | $342.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $297.47 | 2019-2021 | |
| Janssen Biotech, INC. | $291.06 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $258.87 | 2022-2025 | Dupixent |
| Erbe USA INC | $257.34 | 2019-2022 | |
| Celgene Corporation | $255.30 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $228.29 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $160.56 | 2024 | Axios, Overstitch Endoscopic Suturing System Sx |
| Merck Sharp & Dohme LLC | $136.62 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $120.11 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.87 | 2019-2023 | Xifaxan |
| Genzyme Corporation | $104.92 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $90.50 | 2019-2020 | |
| Organon LLC | $85.82 | 2022-2025 | Renflexis, Hadlima |
| Shionogi INC | $84.28 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $82.04 | 2024-2025 | Voquezna |
| Medtronic USA, INC. | $79.16 | 2019 | |
| Medtronic, INC. | $67.13 | 2021-2023 | Pillcam |
| Celltrion USA INC. | $57.52 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $49.99 | 2021-2023 | |
| Ethicon US, LLC | $45.57 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.10 | 2019-2024 | Injectafer |
| Ucb, INC. | $37.30 | 2019 | |
| Olympus America INC. | $35.65 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $24.83 | 2024 | Fujifilm |
| Ardelyx, INC. | $22.73 | 2024 | Ibsrela |
| Allergan, INC. | $22.51 | 2019-2020 | |
| Blueprint Medicines Corporation | $22.28 | 2023 | |
| Ironwood Pharmaceuticals, INC | $21.96 | 2022 | |
| Amgen INC. | $20.76 | 2023 | Amjevita, Avsola |
| Endo Pharmaceuticals INC. | $17.50 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.54 | 2021 | |
| Aimmune Therapeutics, INC. | $14.69 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.82 | 2019 | |
| Romark Laboratories, Lc | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Langer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.